التفاصيل البيبلوغرافية
| العنوان: |
Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of nonmetastatic colorectal cancer. |
| المؤلفون: |
Nguyen, Huu Thinh, Khoa Huynh, Le Anh, Nguyen, Trieu Vu, Tran, Duc Huy, Thu Tran, Thuy Thi, Khang Le, Nguyen Duy, Le, Ngoc-An Trinh, Pham, Truong-Vinh Ngoc, Le, Minh-Triet, Quynh Pham, Thi Mong, Nguyen, Trong Hieu, Van Nguyen, Thien Chi, Nguyen, Thanh Dat, Tran Nguyen, Bui Que, Phan, Minh-Duy, Giang, Hoa, Tran, Le Son |
| المصدر: |
Future Oncology; Nov2022, Vol. 18 Issue 35, p3895-3912, 18p |
| مستخلص: |
Aims: Early detection of colorectal cancer (CRC) provides substantially better survival rates. This study aimed to develop a blood-based screening assay named SPOT-MAS ('screen for the presence of tumor by DNA methylation and size') for early CRC detection with high accuracy. Methods: Plasma cell-free DNA samples from 159 patients with nonmetastatic CRC and 158 healthy controls were simultaneously analyzed for fragment length and methylation profiles. We then employed a deep neural network with fragment length and methylation signatures to build a classification model. Results: The model achieved an area under the curve of 0.989 and a sensitivity of 96.8% at 97% specificity in detecting CRC. External validation of our model showed comparable performance, with an area under the curve of 0.96. Conclusion: SPOT-MAS based on integration of cancer-specific methylation and fragmentomic signatures could provide high accuracy for early-stage CRC detection. A novel blood test for early detection of colorectal cancer. Colorectal cancer is a cancer of the colon or rectum, located at the lower end of the digestive tract. The early detection of colorectal cancer can help people with the disease have a higher chance of survival and a better quality of life. Current screening methods can be invasive, cause discomfort or have low accuracy; therefore newer screening methods are needed. In this study we developed a new screening method, called SPOT-MAS, which works by measuring the signals of cancer DNA in the blood. By combining different characteristics of cancer DNA, SPOT-MAS could distinguish blood samples of people with colorectal cancer from those of healthy individuals with high accuracy. SPOT-MAS technology combines methylation and fragmentomic signatures of blood-based circulating tumor DNA in a multimodal deep-learning analysis to enable early detection of colorectal cancer with high accuracy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Future Oncology is the property of Future Medicine Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher